186 related articles for article (PubMed ID: 17006704)
21. The effect of intravenous iloprost on pulmonary artery hypertension after paediatric congenital heart surgery.
Onan IS; Ozturk E; Yildiz O; Altin HF; Odemis E; Erek E
Interact Cardiovasc Thorac Surg; 2016 Feb; 22(2):194-9. PubMed ID: 26604214
[TBL] [Abstract][Full Text] [Related]
22. Failure of vasoldilator infusion to alter pulmonary diffusing capacity in systemic sclerosis.
Thurm CA; Wigley FM; Dole WP; Wise RA
Am J Med; 1991 May; 90(5):547-52. PubMed ID: 1709338
[TBL] [Abstract][Full Text] [Related]
23. Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.
Ewert R; Opitz CF; Wensel R; Winkler J; Halank M; Felix SB
Clin Res Cardiol; 2007 Apr; 96(4):211-7. PubMed ID: 17294349
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of finger skin temperature in scleroderma patients cyclically treated with iloprost.
Caramaschi P; Biasi D; Canestrini S; Martinelli N; Perbellini L; Carletto A; Pieropan S; Volpe A; Bambara LM
Joint Bone Spine; 2006 Jan; 73(1):57-61. PubMed ID: 16253538
[TBL] [Abstract][Full Text] [Related]
25. Inhaled iloprost to control pulmonary artery hypertension in patients undergoing mitral valve surgery: a prospective, randomized-controlled trial.
Rex S; Schaelte G; Metzelder S; Flier S; de Waal EE; Autschbach R; Rossaint R; Buhre W
Acta Anaesthesiol Scand; 2008 Jan; 52(1):65-72. PubMed ID: 17976224
[TBL] [Abstract][Full Text] [Related]
26. Hemodynamic effects of combination therapy with inhaled nitric oxide and iloprost in patients with pulmonary hypertension and right ventricular dysfunction after high-risk cardiac surgery.
Antoniou T; Koletsis EN; Prokakis C; Rellia P; Thanopoulos A; Theodoraki K; Zarkalis D; Sfyrakis P
J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):459-66. PubMed ID: 23063102
[TBL] [Abstract][Full Text] [Related]
27. Effects of five-day versus one-day infusion of iloprost on the peripheral microcirculation in patients with systemic sclerosis.
Ceru S; Pancera P; Sansone S; Sfondrini G; Codella O; De Sandre G; Lechi A; Lunardi C
Clin Exp Rheumatol; 1997; 15(4):381-5. PubMed ID: 9272298
[TBL] [Abstract][Full Text] [Related]
28. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
[TBL] [Abstract][Full Text] [Related]
29. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis.
Menon N; McAlpine L; Peacock AJ; Madhok R
Arthritis Rheum; 1998 Mar; 41(3):466-9. PubMed ID: 9506575
[TBL] [Abstract][Full Text] [Related]
30. Successful therapy of bosentan-refractory pulmonary arterial hypertension (PAH) with inhalative iloprost.
Ahmadi-Simab K; Lamprecht P; Gross WL
Clin Exp Rheumatol; 2005; 23(3):402-3. PubMed ID: 15971433
[TBL] [Abstract][Full Text] [Related]
31. Iloprost as cyclic five-day infusions in the treatment of scleroderma. An open pilot study in 20 patients treated for one year.
Biasi D; Carletto A; Caramaschi P; Zeminian S; Pacor ML; Corrocher R; Bambara LM
Rev Rhum Engl Ed; 1998 Dec; 65(12):745-50. PubMed ID: 9923042
[TBL] [Abstract][Full Text] [Related]
32. Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis.
Trombetta AC; Pizzorni C; Ruaro B; Paolino S; Sulli A; Smith V; Cutolo M
J Rheumatol; 2016 Nov; 43(11):2033-2041. PubMed ID: 27744392
[TBL] [Abstract][Full Text] [Related]
33. Inhaled iloprost plus oral sildenafil in patients with severe pulmonary arterial hypertension delays the need for lung transplantation.
Lopez-Meseguer M; Berastegui C; Monforte V; Bravo C; Domingo E; Roman A
Transplant Proc; 2013; 45(6):2347-50. PubMed ID: 23953548
[TBL] [Abstract][Full Text] [Related]
34. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease.
Yin N; Kaestle S; Yin J; Hentschel T; Pries AR; Kuppe H; Kuebler WM
Crit Care Med; 2009 Mar; 37(3):980-6. PubMed ID: 19237907
[TBL] [Abstract][Full Text] [Related]
35. Acute hemodynamic response of infused fasudil in patients with pulmonary arterial hypertension: a randomized, controlled, crossover study.
Jiang X; Wang YF; Zhao QH; Jiang R; Wu Y; Peng FH; Xu XQ; Wang L; He J; Jing ZC
Int J Cardiol; 2014 Nov; 177(1):61-5. PubMed ID: 25499341
[TBL] [Abstract][Full Text] [Related]
36. Effect of a sequential therapy of bosentan and iloprost versus a monotherapy with bosentan in the treatment of scleroderma related digital ulcers.
Hafner F; Thomas G; Froehlich H; Steidl K; Brodmann M
Int Angiol; 2011 Oct; 30(5):493-5. PubMed ID: 21804491
[No Abstract] [Full Text] [Related]
37. A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost.
Caramaschi P; Martinelli N; Volpe A; Pieropan S; Tinazzi I; Patuzzo G; Mahamid H; Bambara LM; Biasi D
Clin Rheumatol; 2009 Jul; 28(7):807-13. PubMed ID: 19301062
[TBL] [Abstract][Full Text] [Related]
38. Bosentan improves functional class, pulmonary artery systolic pressure, and DLCO in scleroderma patients with pulmonary hypertension: a possible synergy with iloprost.
Beretta L; Scorza R; Del Papa N; Mazzone A
J Rheumatol; 2006 Sep; 33(9):1915-6; author reply 1916. PubMed ID: 16960959
[No Abstract] [Full Text] [Related]
39. Inhaled iloprost controls pulmonary hypertension after cardiopulmonary bypass.
Theodoraki K; Rellia P; Thanopoulos A; Tsourelis L; Zarkalis D; Sfyrakis P; Antoniou T
Can J Anaesth; 2002 Nov; 49(9):963-7. PubMed ID: 12419726
[TBL] [Abstract][Full Text] [Related]
40. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
